Trials / Completed
CompletedNCT04342819
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- The University of The West Indies · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The mechanistic effects of empagliflozin on platelet function profiles have not yet been ascertained.
Detailed description
Sodium GLucose Transport 2 inhibitors (SGLT2I), including empagliflozin, reduce the likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of which the mechanism has not been fully elucidated. The mechanistic effects of empagliflozin on platelet function profiles have not yet been ascertained. It remains unclear if this reduction in cardiovascular death is mediated by decreased platelet reactivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGLT2 inhibitor | Sodium-Glucose Like Transporter 2 Inhibitor |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2020-04-13
- Last updated
- 2024-09-03
- Results posted
- 2024-09-03
Locations
1 site across 1 country: Trinidad and Tobago
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04342819. Inclusion in this directory is not an endorsement.